MX2012003558A - Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden. - Google Patents

Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden.

Info

Publication number
MX2012003558A
MX2012003558A MX2012003558A MX2012003558A MX2012003558A MX 2012003558 A MX2012003558 A MX 2012003558A MX 2012003558 A MX2012003558 A MX 2012003558A MX 2012003558 A MX2012003558 A MX 2012003558A MX 2012003558 A MX2012003558 A MX 2012003558A
Authority
MX
Mexico
Prior art keywords
epo
recombinant human
purified
purification
pharmaceutical compositions
Prior art date
Application number
MX2012003558A
Other languages
English (en)
Inventor
Walter Hinderer
Stefan Arnold
Original Assignee
Biogenerix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogenerix Ag filed Critical Biogenerix Ag
Publication of MX2012003558A publication Critical patent/MX2012003558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporciona un procedimiento para la producción de eritropoyetina (EPO), en particular EPO humana recombinante (rhEPO) con una composición definida de glicoformas en una forma altamente pura, es decir, con una alta cantidad de isoformas de EPO O-glicosiladas.
MX2012003558A 2009-09-23 2010-09-23 Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden. MX2012003558A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09012120 2009-09-23
PCT/EP2010/005839 WO2011035914A1 (en) 2009-09-23 2010-09-23 Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same

Publications (1)

Publication Number Publication Date
MX2012003558A true MX2012003558A (es) 2012-07-03

Family

ID=41566362

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003558A MX2012003558A (es) 2009-09-23 2010-09-23 Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden.

Country Status (14)

Country Link
US (1) US20120264688A1 (es)
EP (1) EP2480569B1 (es)
JP (1) JP5728016B2 (es)
KR (1) KR20120117728A (es)
CN (1) CN102712688B (es)
AU (1) AU2010297530B2 (es)
BR (1) BR112012006602A2 (es)
CA (1) CA2775012A1 (es)
EA (1) EA022396B1 (es)
IL (1) IL218721A0 (es)
MX (1) MX2012003558A (es)
UA (1) UA107678C2 (es)
WO (1) WO2011035914A1 (es)
ZA (1) ZA201202491B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101443257B1 (ko) * 2011-10-18 2014-09-19 주식회사 종근당 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
US10066001B2 (en) * 2013-03-15 2018-09-04 Apotex Inc. Enhanced liquid formulation stability of erythropoietin alpha through purification processing
WO2014204023A1 (ko) * 2013-06-17 2014-12-24 씨제이헬스케어 주식회사 신규한 다베포에틴 알파의 정제 방법
CA2920191C (en) 2013-07-18 2022-03-01 Children's Hospital Medical Center Methods of improving titer in transfection-based production systems using eukaryotic cells
US10078081B2 (en) 2014-03-05 2018-09-18 GlycoScientific LLC Isotopically labeled glycans and methods for producing the same
JP6906497B2 (ja) * 2016-03-09 2021-07-21 Ｊｃｒファーマ株式会社 変異型ヒトエリスロポエチンの製造方法
JP6920280B2 (ja) * 2016-03-31 2021-08-18 株式会社カネカ 精製されたネコ由来エリスロポエチンの製造方法
DK3613486T3 (da) * 2018-08-24 2021-01-04 Uga Biopharma Gmbh Metode og anlæg til rengøring af epo og/eller et epo-derivat
CN115015415A (zh) * 2022-05-30 2022-09-06 科兴生物制药股份有限公司 重组人促红细胞生成素的含量检测方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
IL79176A (en) 1985-06-20 1992-06-21 Kirin Amgen Inc Process for the recovery of erythropoietin from a fluid
DE3785086T2 (de) 1986-06-04 1993-07-08 Agency Ind Science Techn Zubereitung fuer zellkultur und ihre verwendung.
JP2520681B2 (ja) 1986-08-04 1996-07-31 ザ ユニバーシティ オブ ニュー サウス ウェールズ 生合成のヒトの成長ホルモン製品
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
EP0343635B1 (en) 1988-05-25 1994-08-24 Teijin Limited Process for continuously culturing adherent animal cells
WO1991005867A1 (en) 1989-10-13 1991-05-02 Amgen Inc. Erythropoietin isoforms
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
KR0176693B1 (ko) 1989-12-22 1999-04-01 레지널드 디. 쇼트보그; 제롬 반 쥘렌 조절요소를 사용한 내인성 유전자의 발현을 변형시키는 방법
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
DE4115722A1 (de) 1991-05-14 1992-11-19 Boehringer Mannheim Gmbh Serumfreies medium zur kultivierung von saeugerzellen
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
CA2309810C (en) * 1997-12-03 2014-07-08 Roche Diagnostics Gmbh Erythropoietin with high specific activity
BR9917606A (pt) * 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
ATE291436T2 (de) * 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
US20020045192A1 (en) * 2001-09-19 2002-04-18 St. Jude Children's Research Hospital Arf and HDM2 interaction domains and methods of use thereof
US6930086B2 (en) * 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
BR0214568A (pt) * 2001-11-28 2004-11-03 Sandoz Ag Purificação cromatográfica de eritropoietina humana recombinante
ATE363541T1 (de) 2002-03-26 2007-06-15 Lek Tovarna Farmacevtskih Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
PT1428878E (pt) 2002-12-13 2008-11-18 Bioceuticals Arzneimittel Ag Processo para a produção e purificação de eritropoietina
EP1537876A1 (en) 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
CA2551916C (en) * 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2006079155A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
US20090105462A1 (en) * 2006-11-09 2009-04-23 Ivarie Robert D Glycosylated erythropoietin
KR20090090328A (ko) * 2006-11-09 2009-08-25 시나게바 바이오파르마, 코포레이션 조류 유래 에리트로포이어틴
CN107022020A (zh) * 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途

Also Published As

Publication number Publication date
BR112012006602A2 (pt) 2019-09-24
WO2011035914A1 (en) 2011-03-31
KR20120117728A (ko) 2012-10-24
UA107678C2 (uk) 2015-02-10
US20120264688A1 (en) 2012-10-18
CN102712688B (zh) 2015-06-24
JP5728016B2 (ja) 2015-06-03
EP2480569B1 (en) 2016-04-13
CA2775012A1 (en) 2011-03-31
AU2010297530B2 (en) 2013-12-19
CN102712688A (zh) 2012-10-03
EA022396B1 (ru) 2015-12-30
JP2013505276A (ja) 2013-02-14
AU2010297530A1 (en) 2012-04-26
IL218721A0 (en) 2012-06-28
EA201290135A1 (ru) 2012-10-30
EP2480569A1 (en) 2012-08-01
ZA201202491B (en) 2012-12-27

Similar Documents

Publication Publication Date Title
MX2012003558A (es) Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden.
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
BRPI0520498B8 (pt) processo para fabricação de interferon beta humano recombinante glicosilado, e uso de um meio de cultura isento de soro
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
EP2415749A4 (en) NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE
MX368790B (es) Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
MX2011007583A (es) Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos.
BR112012015576A2 (pt) "cerâmica de vidro de dissilicato de lítio, método para sua fabricação e seu uso"
MY151413A (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
NZ591146A (en) Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills
UA104031C2 (uk) Диференціація мезенхімальних стовбурових клітин
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
IN2014CN03937A (es)
NZ733366A (en) Purification of iduronate-2-sulfatase
MY166789A (en) Arginine salts and their uses for the treatment of illnesses in the oral cavity
MX344815B (es) Metodo para purificar el factor estimulante de colonias de granulocitos humano a partir de e. coli recombinante.
AU2016219650A1 (en) Compositions and methods for extended therapy with aminopyridines
MX2009004108A (es) Compuestos de tetrahidropirrolopiracina sustituidos teniendo afinidad al canal kcnq2/3 k+ y su uso en farmacos.
MX2010002557A (es) Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo.
MY150931A (en) Substituted oxazolidinones and their use
NZ601142A (en) Composition for improving brain function and method for improving brain function
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
TN2011000595A1 (en) Substituted piperidines
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: NERVIANO MEDICAL SCIENCES S.R.L.*

Owner name: EVONIK DEGUSSA GMBH

FA Abandonment or withdrawal